Aim: Brinzolamide (BNZ) is a carbonic anhydrase inhibitor commonly used for the treatment of glaucoma. The aim of this study was to prepare BNZ loaded chitosan-pectin mucoadhesive nanocapsules (CPNCs) by polyelectrolyte complex coacervation method for ocular delivery and evaluated for its anti glaucoma efficacy.
Methods: The prepared CPNCs were characterized for their particle size, polydispersity index, zeta-potential, surface morphology, entrapment efficiency, drug loading efficiency, mucoadhesive strength in-vitro and ex-vivo release. The pharmacodynamic studies were conducted for CPNCs on glaucoma induced rabbit eye model and compared with marketed product.
Result And Discussion: All the formulated CPNCs exhibited the size range from 217.01 ± 0.21 to 240.05 ± 0.08 nm and appropriate physico-chemical parameters, and depicted a couple of erosion- diffusion release of BNZ over a time of 8 h. Ex-vivo corneal permeation study concluded that BNZ loaded CPNCs crosses the cornea potentially higher rate as compared to the marketed product. In pharmacodynamic study, greater intraocular pressure lowering effect was achieved by CPNCs as compared to marketed drug product.
Conclusion: The result concluded that CPNCs are a feasible choice to conventional eye drops because of its ability to improve the bioavailability via its longer precorneal retention time and its ability to sustained release of the drug.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2019.10.219 | DOI Listing |
Planta
January 2025
Department of Fruit Science, College of Horticulture, Dr Yashwant Singh Parmar University of Horticulture and Forestry, Solan, Himachal Pradesh, 173230, India.
This review serves as a critical framework for guiding future research into the causes of russeting and the development of effective control strategies to enhance fruit quality. Russeting is a condition characterized by the formation of brown, corky patches on fruit skin which significantly impairs both the quality and market value of apples. This phenomenon arises from a complex interplay of various biotic and abiotic factors.
View Article and Find Full Text PDFJ Comp Eff Res
January 2025
Mitsubishi Tanabe Pharma America, Inc., Health Economics and Outcomes Research (HEOR), Medical Affairs, Jersey City, NJ, 07310 USA.
To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava IV, Mitsubishi Tanabe Pharma America [MTPA], hereafter "IV edaravone") in a real-world setting. IV edaravone is US FDA approved for the treatment of ALS and was shown in clinical trials to slow the rate of physical functional decline. This retrospective observational analysis included PALS continuously enrolled in Optum's Clinformatics Data Mart between 8 August 2017 and 31 December 2021.
View Article and Find Full Text PDFTidsskr Nor Laegeforen
January 2025
Institutt for psykologi, Oslo Nye Høyskole.
Background: Studies from 2003 and 2008 indicated that 7-8 % of adult women in Norway had undergone cosmetic surgery. As there is little research available on the current situation, the main purpose of this study was to map the use of, desire for and social acceptance of cosmetic surgery. We also wanted to identify differences in demographic and psychosocial factors between women who have undergone cosmetic surgery, those who desire such surgery and those who do not.
View Article and Find Full Text PDFFront Sports Act Living
January 2025
Department of Kinesiology, Texas Christian University, Fort Worth, TX, United States.
Introduction: Since the early 2000s, the video game industry has seen extraordinary booms in product development and market growth, with the total number of video game players globally reaching 2.69 billion by the end of 2020. Despite the rapid growth of the industry, there is little recent data investigating the time adult video game players spend sedentary playing video games and the time they spent engaged in physical activity.
View Article and Find Full Text PDFBMC Pharmacol Toxicol
January 2025
Clinical Research Unit, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab constitute a pivotal class of therapeutic agents employed in the clinical management of Psoriasis, a chronic immune-mediated skin disorder. Notwithstanding their therapeutic efficacy, concerns have arisen due to the emergence of multiple adverse events (AEs) associated with their usage. This study aims to provide a comprehensive examination of the distribution and characteristics of these AEs concerning IL-23 and IL-12/23 inhibitors, with a specific focus on guselkumab, tildrakizumab, risankizumab, and ustekinumab.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!